BT2

BT2 is a BCKDC kinase (BDK) inhibitor with an IC50 of 3.19 μM. BT2 binding to BDK triggers helix movements in the N-terminal domain, resulting in the dissociation of BDK from the branched-chain α-ketoacid dehydrogenase complex (BCKDC) [1]. BT2 (compound 4) is also a potent and selective Mcl-1 inhibitor with a Ki value of 59 μM[2].

Product Specifications

CAS Number

[34576-94-8]

Product Name Alternative

BAY1163877

UNSPSC

12352005

Hazard Statement

H315, H319, H335

Target

Bcl-2 Family

Type

Reference compound

Related Pathways

Apoptosis

Applications

Cancer-Kinase/protease

Field of Research

Metabolic Disease

Assay Protocol

https://www.medchemexpress.com/bt2.html

Concentration

10mM

Purity

99.85

Solubility

DMSO : 62.5 mg/mL (ultrasonic)

Smiles

O=C(O)C1=C(C2=CC=C(C=C2S1)Cl)Cl

Molecular Formula

C9H4Cl2O2S

Molecular Weight

247.10

Precautions

H315, H319, H335

References & Citations

[1]Tso SC, et al. Benzothiophene carboxylate derivatives as novel allosteric inhibitors of branched-chain α-ketoacid dehydrogenase kinase. J Biol Chem. 2014 Jul 25;289 (30) :20583-93.|[2]Friberg A, et al. Discovery of potent myeloid cell leukemia 1 (Mcl-1) inhibitors using fragment-based methods and structure-based design. J Med Chem. 2013 Jan 10;56 (1) :15-30.